Caroline Helwick

3 weeks ago | ascopost.com | Caroline Helwick

The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inhibitor pembrolizumab and chemotherapy, followed by pembrolizumab plus maintenance with the PARP inhibitor olaparib, in newly diagnosed patients.1 In addition, pembrolizumab plus chemotherapy, without olaparib, offered benefit in certain patient subsets not receiving the monoclonal antibody...

4 weeks ago | ascopost.com | Caroline Helwick

Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed by pembrolizumab maintenance, as the upfront standard of care for high-risk, locally advanced cervical cancer.

1 month ago | ascopost.com | Caroline Helwick

Today’s oncologists are blessed with an abundance of therapies for HER2-positive early breast cancer, but this comes with the challenge of selecting among them. At the 2025 Miami Breast Cancer Conference, Sara A. Hurvitz, MD, FACP, offered insight on common clinical scenarios.

1 month ago | ascopost.com | Caroline Helwick

The phase III DUO-E study evaluated the addition of the monoclonal antibody durvalumab to chemotherapy, and the benefit of maintenance durvalumab, with and without the PARP inhibitor olaparib, in advanced endometrial cancer. As reported this past year,1 the inclusion of durvalumab reduced the risk of disease progression by 29%; the further addition of olaparib reduced the risk by 45% in the intent-to-treat population.

1 month ago | ascopost.com | Caroline Helwick

In the phase III JCOG1411/FLORA trial of patients with untreated advanced-stage, very low–tumor burden follicular lymphoma, rituximab induction delayed disease progression to high–tumor burden follicular lymphoma and delayed the initiation of cytotoxic chemotherapy, according to Japanese investigators who reported the findings at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition.1 “We recommend the early administration of rituximab as an initial treatment approach for...